Roxatidine

From Self-sufficiency
Revision as of 21:33, 18 August 2010 by Edgar181 (Talk) (Removed Category:Acetates; Adding category Category:Acetate esters (using HotCat))

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Roxatidine
250px
Systematic (IUPAC) name
2-oxo-2-(3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino)ethyl acetate
Clinical data
Routes of
administration
Oral
Pharmacokinetic data
Bioavailability 80–90%
Protein binding 5–7%
Metabolism Hepatic deacetylation
Minor involvement of CYP2D6 and CYP2A6
Biological half-life 5–7 hours
Excretion Renal
Identifiers
CAS Number 78628-28-1
ATC code A02BA06 (WHO)
PubChem CID 5105
Chemical data
Formula C19H28N2O4
Molar mass 348.437 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Roxatidine acetate is a specific and competitive H2 receptor antagonist. The antisecretory effect of roxatidine acetate is mediated by its main metabolite, roxatidine. Pharmacodynamic studies revealed that 150 mg of roxatidine acetate were optimal in suppressing gastric acid secretion, and that a single bedtime dose of 150 mg was more effective than a dose of 75 mg twice daily in terms of inhibiting nocturnal acid secretion.[citation needed]

Roxatidine acetate has no antiandrogenic effects and does not influence drug-metabolizing enzymes in the liver.[citation needed]

It is currently sold in South Africa under the tradename Roxit.


de:Roxatidin